The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.

PTM Substantial Shareholders Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Platinum Asset Management Limited (PTM). However, you won't ...

Oral insulin could still be a reality, says Novo NordiskLast October Novo Nordisk announced that it had shelved plans to bring the world’s first oral insulin to market . But the company has just ...

Typically, the hormone insulin helps move glucose from your blood to your cells, where it’s used for energy. But with type 2 diabetes, your body’s cells aren’t able to respond to insulin as ...

Type 2 diabetes is a chronic condition characterized by high blood glucose levels, resulting from the body’s ineffective response to insulin or insufficient insulin production. Symptoms of type ...

Platinum Group Metals Ltd. Completes Non-Brokered Private Placement Vancouver, British Columbia and Johannesburg, South Africa-- (Newsfile Corp. - May 29, 2025) - Platinum Group Metals Ltd. (TSX: PTM) ...

Fatigue and feeling very tired are symptoms of unmanaged blood sugar levels. “Simply put, when your body doesn’t have sufficient amounts of insulin, the sugar is staying in our blood rather ...

Frank R. Hallam is the founder of Platinum Group Metals Ltd. (2003), holding the title of President, Chief Executive Officer & Director. Mr. Hallam was the founder of Nextraction Energy Corp ...